Advertisement

Topics

IMMU – 132 Antibody-Drug Conjugate Improves Responses In Metastatic Triple-Negative Breast Cancer

11:57 EST 12 Dec 2017 | Cancer Connect

Treatment with IMMU-132 (sacituzumab govitecan) elicited an overall response rate of 34 percent in patients with heavily pretreated metastatic triple-negative […]

The post IMMU – 132 Antibody-Drug Conjugate Improves Responses In Metastatic Triple-Negative Breast Cancer appeared first on .

Original Article: IMMU – 132 Antibody-Drug Conjugate Improves Responses In Metastatic Triple-Negative Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "IMMU – 132 Antibody-Drug Conjugate Improves Responses In Metastatic Triple-Negative Breast Cancer"

Advertisement
Quick Search
Advertisement
Advertisement